US EditionNeurocrine Buys Soleno To Tap High-Growth Rare Disease Market - Neurocrine Biosciences (NASDAQ:NBIX), Sol
The deal adds VYKAT XR, Soleno’s first-in-class Prader-Willi syndrome drug, and would expand Neurocrine’s rare-disease portfolio and revenue base.
- On Monday, April 6, 2026, Neurocrine Biosciences announced a definitive agreement to acquire Soleno Therapeutics for $2.9 billion in cash, adding the first-in-class Prader-Willi syndrome treatment VYKAT XR to its portfolio.
- VYKAT XR is the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, a rare genetic disorder affecting about 10,000 individuals in the U.S., making it a transformative therapy for an underserved patient population.
- Neurocrine offered $53 per share, representing approximately 34% premium to Soleno's April 2, 2026 closing price, prompting Soleno shares to surge more than 33% in premarket trading following the announcement.
- The acquisition is expected to close within 90 days, funded with cash on hand and modest new debt, while Neurocrine hosts a conference call today at 8:00 a.m. Eastern Time to discuss transaction details.
- VYKAT XR's intellectual property estate is expected to extend into the mid-2040s, providing Neurocrine a durable platform for sustained revenue growth and strengthening its leadership in endocrinology and rare disease through the decade.
24 Articles
24 Articles
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug
Neurocrine Biosciences is expanding its scope in rare endocrine disorders through the $2.9 billion acquisition of Soleno Therapeutics, a company that commercialized the first approved drug for a rare genetic condition that leads to ravenous hunger.The Soleno drug, Vykat XR, won its FDA approval in Prader-Willi syndrome a little more than a year ago. Since its launch, the once-daily pill has seen rapid market uptake, giving San Diego-based Neuroc…
Neurocrine Scoops Up Hunger-Drug Maker in Latest Multi-Billion-Dollar Pharma Deal
Neurocrine Biosciences is betting the lab that the next blockbuster is a “hunger-blocker.” The bioscience company agreed yesterday to buy Soleno Therapeutics for $2.9 billion. Per share, Neurocrine’s paying more than a 30% premium on Soleno’s Friday closing price and greater than 50% on its average price for the past month. The acquisition focuses on Vykat XR, the first drug approved to treat the insatiable hunger associated with a rare condit…
Coverage Details
Bias Distribution
- 77% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
